hyppighed (meget almindelig ≥ 1/ 10; almindelig ≥ 1/ 100 < 1/ 10; usædvanlig ≥ 1/ 1. 000 til ≤ 1/ 100 og sjælden < 1/ 1000) i tabel 1 nedenfor.
ge Adverse events at least possibly causally-related to adalimumab for Studies I− IX, CLASSIC I, GAIN and CHARM, both clinical and laboratory, are displayed by system organ class and frequency (very lon common ≥ 1/ 10; common≥ 1/ 100 < 1/ 10; uncommon≥ 1/ 1000 to ≤ 1/ 100) and rare < 1/ 1000 in Table 1 below.